ART initiates clinical study for SoftScan optical breast imaging system
In collaboration with the Central Alberta Medical Imaging Services (CAMIS), Advanced Research Technologies (ART) announced that it will conduct clinical studies as part of the U.S. Food and Drug Administration Pre-market approval application for SoftScan. This study represents the final stage prior to commercializing SoftScan, and optical breast imaging system that is designed to improve the diagnosis and treatment of breast cancer.
Originally developed in Canada, SoftScan was designed as a complement to mammography that would eventually be used for the detection and monitoring of treatment for breast cancer. As a non-invasive and painless system, it uses time-domain optical imaging technology that is capable of providing precise characterization of benign and malignant breast tumors.
Originally developed in Canada, SoftScan was designed as a complement to mammography that would eventually be used for the detection and monitoring of treatment for breast cancer. As a non-invasive and painless system, it uses time-domain optical imaging technology that is capable of providing precise characterization of benign and malignant breast tumors.